TY - JOUR
T1 - Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer
T2 - An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)
AU - Grossi, Francesco
AU - Fasola, Gianpiero
AU - Rossetto, Ciro
AU - Spizzo, Riccardo
AU - Meduri, Stefano
AU - Sibau, Angela
AU - Vigevani, Enrico
AU - Tumolo, Salvatore
AU - Adami, Gianna
AU - Sacco, Cosimo
AU - Recchia, Leonardo
AU - Rizzato, Simona
AU - Ceschia, Tino
AU - Belvedere, Ornella
PY - 2006/4
Y1 - 2006/4
N2 - This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age
AB - This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age
KW - Docetaxel
KW - Irinotecan
KW - Non-small cell lung cancer
KW - Phase II study
KW - Second line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=33644779559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644779559&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2005.11.013
DO - 10.1016/j.lungcan.2005.11.013
M3 - Article
C2 - 16483688
AN - SCOPUS:33644779559
VL - 52
SP - 89
EP - 92
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 1
ER -